GERN Quote, Financials, Valuation and Earnings

BioMarin Pharmaceutical, Inc. has a net margin of -64.86% compared to Geron Corp.'s net margin of -5.33%. Geron Corp.'s return on equity of -33.5% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.

Geron Corp. has a consensus price target of $3.40, signalling upside risk potential of 102.38%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that Geron Corp. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Geron Corp. is more attractive than BioMarin Pharmaceutical, Inc..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $48M, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. Geron Corp.'s net income of -$31.1M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Geron Corp.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 6.09x versus 3.73x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -64.86% compared to Geron Corp.'s net margin of -112.81%. Geron Corp.'s return on equity of -33.5% beat Ionis Pharmaceuticals, Inc.'s return on equity of -67.97%.

Geron Corp. has a consensus price target of $3.40, signalling upside risk potential of 102.38%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $93.76 which suggests that it could grow by 15.54%. Given that Geron Corp. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Ionis Pharmaceuticals, Inc..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.94%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $48M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $203M. Geron Corp.'s net income of -$31.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$229M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 6.09x versus 14.25x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -64.86% compared to Geron Corp.'s net margin of -316.61%. Geron Corp.'s return on equity of -33.5% beat Plus Therapeutics, Inc.'s return on equity of --.

Geron Corp. has a consensus price target of $3.40, signalling upside risk potential of 102.38%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1716.98%. Given that Plus Therapeutics, Inc. has higher upside potential than Geron Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Geron Corp..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $48M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Geron Corp.'s net income of -$31.1M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 6.09x versus 4.85x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -64.86% compared to Geron Corp.'s net margin of -304.24%. Geron Corp.'s return on equity of -33.5% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

Geron Corp. has a consensus price target of $3.40, signalling upside risk potential of 102.38%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 82.95%. Given that Geron Corp. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe Geron Corp. is more attractive than Recursion Pharmaceuticals, Inc..

Geron Corp. has a beta of 0.620, which suggesting that the stock is 38.038% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $48M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. Geron Corp.'s net income of -$31.1M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 6.09x versus 22.04x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.